Targeting CD24 restores neutrophil clearance, reduces pathogenic neutrophil–megakaryocyte interactions, and mitigates disease progression in preclinical models, positioning CD24 as a promising innate immune checkpoint and potential therapeutic target in MPN. The gene discussed is CD24; the disease is myeloproliferative disorder.